MedPath

Bronchiolitis obliterans syndrome and other allo-reactive lung syndromes after allogeinic hematopoietic stem cell transplantation Is early prediction of bronchiolitis obliterans possible by using biomarkers possible?

Recruiting
Conditions
afstoting na beenmergtransplantatie
chronic lung rejection bronchiolitis obliterans
lung rejection after hematopoietic stemcell transplantation
10038716
Registration Number
NL-OMON44102
Lead Sponsor
niversitair Medisch Centrum Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
360
Inclusion Criteria

Patients whom are selected for hematopoietic stem cell transplantation

Exclusion Criteria

no informed consent
all patients after hematopoietic stem cell transplantation will be included except patients that do not want to participate in this study.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Identifying biomarkers in the peripheral blood that predict BOS by a sgnificant<br /><br>elevation before a lungfunction decline occurs (i.e. a drop in FEV1 of 20%)<br /><br>after allogeneic hemtopoietic stem cell transplantation.<br /><br>. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>To determine the incidence and outcome of allo-reactive lung syndromes (i.e.<br /><br>BOS and other ARLS) in patients that underwent allogeneic haematopoietic stem<br /><br>cell transplantation.</p><br>
© Copyright 2025. All Rights Reserved by MedPath